Navigation Links
Clinical Study Proves Pollogen's TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks

TEL AVIV, Israel, August 18 /PRNewswire/ -- Pollogen's TriPollar(TM) technology, the most advanced 3rd generation radio frequency solution for facial and body contouring, has been clinically proven to be effective in treating stretch marks or striae distensae. The peer reviewed paper entitled "Treatment of striae distensae with a TriPollar radiofrequency device: a pilot study" authored by Dr Manuskiatti et al, has been published in the Journal of Dermatological Treatment. The abstract is available online at:

In the clinical study, seventeen females with stretch marks underwent six weekly treatments with the apollo(TM) device-Pollogen's latest aesthetic solution based on TriPollar(TM) technology. Results showed that at one week after the final (sixth) treatment, 38.2% and 11.8% of the patients were assessed to have 25-50% and 51-75% improvement in the appearance of their stretch marks, respectively. The long term effect of the treatment was confirmed during the 6 weeks follow up which showed that a higher percentage of the patients were rated to have improvement of their stretch marks, including 26.5% and 5.9% showing 51-75% and >75% improvement, respectively. None of the participants were rated as having no improvement in their clinical appearance of stretch marks. Patient satisfaction was also measured and 65% of patients reported that they were very satisfied with the treatment, 23% were satisfied and 12% were slightly satisfied.

Dr. Manuskiatti commented: "Stretch marks are a skin condition that has been traditionally very challenging to treat. The study confirms that collagen remodeling induced by RF heating is an effective mechanism for improving the surface appearance of stretch marks. I am delighted that TriPollar(TM) technology delivered significant measurable results that were maintained during the long term follow-up examination and that patients reported a pain-free and pleasant experience".

Company Founder and CEO, Dr Zion Azar, stated: "Pollogen is dedicated to providing patients with a wide range of aesthetic solutions. In addition to facial rejuvenation and body sculpting, TriPollar(TM) is a fast, effective, non-invasive way to significantly reduce stretch marks. A primary audience for this treatment is post-pregnancy women who would like to eliminate abdominal stretch marks. Pollogen is delighted with the results of the clinical trial which provides clear scientific evidence supporting the safety and effectiveness of TriPollar(TM) technology."

About Pollogen:

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at

    Abigail Marks
    Tel: +972-54-244-5807

SOURCE Pollogen
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
4. Radius Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
5. Project Zero Delay Accelerates Drugs Path to Clinical Trial
6. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
7. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
8. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
9. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
Post Your Comments:
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... November 25, 2015 Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ... and regulatory/legal strategies all play a key role ... GBI Research . --> Developmental, ... key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the ... they need it—presented a third donation of $35,000 to bolster progress at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to ... of the Create Real Impact awards. California Casualty is proud to support ... tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):